Table 1.

Baseline characteristics of the 50,981 included individuals, HIV-CAUSAL Collaboration 2000–2015.

Baseline characteristics		Eligible	Initiators of ART (%)	Median [IQR] follow-up time, years
CD4 count, cells/mm3	<100	4021 (8%)	86	3.8	[1.9, 6.8]
	100 – 200	4820 (9%)	86	4	[2.0, 6.8]
	200 – 350	11581 (23%)	76	3.9	[2.0, 6.5]
	350 – 500	12557 (25%)	60	3.7	[1.9, 6.0]
	>500	18002 (35%)	44	3.3	[1.7, 5.6]
HIV-RNA, copies/mL	<10000	14491 (28%)	48	3.5	[1.8, 5.9]
	10000 – 100000	22670 (44%)	64	3.8	[1.9, 6.3]
	>100000	13820 (27%)	77	3.7	[1.8, 6.4]
Sex	Male	40933 (80%)	63	3.7	[1.9, 6.2]
	Female	10048 (20%)	62	3.5	[1.8, 6.3]
Age, years	< 35	25001 (41%)	57	3.3	[1.8, 5.8]
	35 – 50	21015 (10%)	67	3.9	[2.1, 6.5]
	>50	4965 (31%)	75	3.7	[2.0, 6.3]
Mode of HIV acquisition	Heterosexual	15743 (31%)	65	3.7	[1.8, 6.3]
	Homo/bi-sexual	29482 (58%)	63	3.8	[2.0, 6.3]
	Injection drug-use	2279 (4%)	54	2.5	[1.3, 5.4]
	Other/unknown	3477 (7%)	59	3.3	[1.8, 5.5]
Calendar year	2000–2004	14894 (29%)	61	6.7	[3.3, 9.8]
	2005–2009	19254 (38%)	67	4.5	[2.7, 6.0]
	2010 – 2015	16833 (33%)	59	1.9	[1.2, 2.8]
Region of origin	Western countries	19751 (39%)	68	3.8	[2.0, 6.3]
	Sub-saharan Africa	2233 (4%)	66	3.7	[1.8, 6.2]
	Rest of the world	4407 (9%)	61	3.3	[1.8, 5.8]
	Unknown	24590 (48%)	59	3.6	[1.8, 6.3]
Ethnicity	White	20714 (41%)	63	3.9	[2.0, 6.7]
	Black	7991 (16%)	59	3.4	[1.8, 5.9]
	Other/unknown	22276 (44%)	64	3.5	[1.8, 5.9]
Testing for transmitted drug resistance	No	28820 (56%)	63	3.4	[1.8, 6.5]
	Yes	22161 (43%)	63	3.8	[2.1, 6.0]
Overall		50981 (100%)	62	3.7	[1.9, 6.5]